An update on the global use of risk assessment models and thromboprophylaxis in hospitalized patients with medical illnesses from the World Thrombosis Day steering committee: Systematic review and meta‐analysis

Venous thromboembolism (VTE) is a leading cause of cardiovascular morbidity and mortality. The majority of VTE events are hospital‐associated. In 2008, the Epidemiologic International Day for the Evaluation of Patients at Risk for Venous Thromboembolism in the Acute Hospital Care Setting (ENDORSE) multinational cross‐sectional study reported that only approximately 40% of medical patients at risk of VTE received adequate thromboprophylaxis.

[1]  S. Goodacre,et al.  Risk assessment models for venous thromboembolism in hospitalised adult patients: a systematic review , 2021, BMJ Open.

[2]  M. Qiu,et al.  External validation of the IMPROVE-DD risk assessment model for venous thromboembolism among inpatients with COVID-19 , 2021, Journal of Thrombosis and Thrombolysis.

[3]  W. Ageno,et al.  Global reporting of pulmonary embolism–related deaths in the World Health Organization mortality database: Vital registration data from 123 countries , 2021, Research and practice in thrombosis and haemostasis.

[4]  S. Davis,et al.  Which is the best model to assess risk for venous thromboembolism in hospitalised patients? , 2021, BMJ.

[5]  S. Konstantinides,et al.  Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition , 2021, Research and practice in thrombosis and haemostasis.

[6]  G. Raskob,et al.  Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients , 2021, Journal of the American Heart Association.

[7]  M. Barish,et al.  Validation of the IMPROVE‐DD risk assessment model for venous thromboembolism among hospitalized patients with COVID‐19 , 2021, Research and Practice in Thrombosis and Haemostasis.

[8]  Syed Sikandar Shah,et al.  The rational use of thromboprophylaxis therapy in hospitalized patients and the perspectives of health care providers in Northern Cyprus , 2020, PloS one.

[9]  J. Boombhi,et al.  Incidence of Venous Thromboembolism, Risk Factors and Prophylaxis in Hospitalized Patients in the South West Region of Cameroon , 2020, Vascular health and risk management.

[10]  A. Spyropoulos,et al.  New Paradigms of Extended Thromboprophylaxis in Medically Ill Patients , 2020, Journal of clinical medicine.

[11]  L. Mbuagbaw,et al.  Prognostic factors for VTE and Bleeding in Hospitalized Medical Patients: a systematic review and meta-analysis. , 2020, Blood.

[12]  L. Leibovici,et al.  Venous Thromboembolism Prophylaxis in Acute Medically Ill Patients: A Retrospective Cohort Study , 2019, Blood.

[13]  B. Hunt.  Preventing hospital associated venous thromboembolism , 2019, BMJ.

[14]  V. Chopra,et al.  Use of Venous Thromboembolism Prophylaxis in Hospitalized Patients , 2018, JAMA internal medicine.

[15]  M. Ayalew,et al.  Appropriateness of Pharmacologic Prophylaxis against Deep Vein Thrombosis in Medical Wards of an Ethiopian Referral Hospital , 2018, International journal of vascular medicine.

[16]  C. Nejjari,et al.  Evaluation and management of thromboprophylaxis in Moroccan hospitals at national level: the Avail-MoNa study , 2018, Journal of Thrombosis and Thrombolysis.

[17]  A. Undas,et al.  Real-life use of thromboprophylaxis in patients hospitalized for pulmonary disorders: A single-center retrospective study. , 2018, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[18]  F. Farhat,et al.  Evaluation of deep vein thrombosis prophylaxis in a general hospital , 2018, Jornal vascular brasileiro.

[19]  N. Kucher,et al.  Risk assessment models for venous thromboembolism in acutely ill medical patients , 2017, Thrombosis and Haemostasis.

[20]  Meghan N. Jeffres,et al.  A Retrospective Cohort Analysis of Pharmacologic VTE Prophylaxis and Padua Prediction Score in Hospitalized Patients With Chronic Liver Disease , 2017, Journal of pharmacy practice.

[21]  A. Spyropoulos,et al.  Cost-of-illness model for venous thromboembolism. , 2016, Thrombosis research.

[22]  G. Raskob,et al.  Global Burden of Thrombosis: Epidemiologic Aspects. , 2016, Circulation research.

[23]  F. Germini,et al.  Padua prediction score or clinical judgment for decision making on antithrombotic prophylaxis: a quasi-randomized controlled trial , 2016, Journal of Thrombosis and Thrombolysis.

[24]  T. Gaziano,et al.  25 by 25: Achieving Global Reduction in Cardiovascular Mortality , 2016, Current Cardiology Reports.

[25]  F. Piovella,et al.  European Union-28: An annualised cost-of-illness model for venous thromboembolism , 2015, Thrombosis and Haemostasis.

[26]  M. Ruggieri,et al.  Perception of Thromboembolism Risk: Differences between the Departments of Internal Medicine and Emergency Medicine. , 2016, The Keio journal of medicine.

[27]  G. Raskob,et al.  Global public awareness of venous thromboembolism , 2015, Journal of thrombosis and haemostasis : JTH.

[28]  N. Younes,et al.  Evaluation of venous thromboembolism prophylaxis after the introduction of an institutional guideline: Extent of application and implementation of its recommendations. , 2015, Journal of vascular nursing : official publication of the Society for Peripheral Vascular Nursing.

[29]  D. Aujesky,et al.  Predictors of thromboprophylaxis in hospitalised medical patients , 2015, Thrombosis and Haemostasis.

[30]  S. Belhamidi,et al.  [The PROMET study: Prophylaxis for venous thromboembolic disease in at-risk patients hospitalized in Algeria]. , 2015, Journal des maladies vasculaires.

[31]  M. Fallahi,et al.  Adherence to Venous Thromboprophylaxis Guidelines for Medical and Surgical Inpatients of Teaching Hospitals, Shiraz-Iran , 2015, Tanaffos.

[32]  A. Eichorn,et al.  External Validation of the Risk Assessment Model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for Medical Patients in a Tertiary Health System , 2014, Journal of the American Heart Association.

[33]  J. Nieto,et al.  Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients. A retrospective multicenter study. , 2014, European journal of internal medicine.

[34]  V. Chopra,et al.  Hospital performance for pharmacologic venous thromboembolism prophylaxis and rate of venous thromboembolism : a cohort study. , 2014, JAMA internal medicine.

[35]  A. Tabares,et al.  Risk of venous thromboembolic disease and adequacy of prophylaxis in hospitalized patients in Argentina: a multicentric cross-sectional study , 2014, Thrombosis Journal.

[36]  N. Heddle,et al.  External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR) , 2014, Thrombosis and Haemostasis.

[37]  N. Okubadejo,et al.  Epidemiological African day for evaluation of patients at risk of venous thrombosis in acute hospital care settings , 2014, Cardiovascular journal of Africa.

[38]  D. Neuberg,et al.  Pattern of frequent but nontargeted pharmacologic thromboprophylaxis for hospitalized patients with cancer at academic medical centers: a prospective, cross-sectional, multicenter study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  S. Barreto,et al.  Assessment of characteristics associated with pharmacologic thromboprophylaxis use in hospitalized patients: a cohort study of 10 016 patients , 2013, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[40]  P. Prandoni,et al.  Physicians’ compliance with the Padua Prediction Score for preventing venous thromboembolism among hospitalized medical patients , 2013, Journal of thrombosis and haemostasis : JTH.

[41]  M. Hashemian,et al.  AssessMent of ProphylAxis for VenouS ThromboembolIsm in Hospitalized Patients , 2012, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[42]  P. Wessels,et al.  DVT prophylaxis in relation to patient risk profiling - TUNE-IN study. , 2012, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[43]  A. Panju,et al.  Evaluation of the use of venous thromboembolism prophylaxis in hospitalised medical patients. , 2011, The journal of the Royal College of Physicians of Edinburgh.

[44]  M. Ndiaye,et al.  A cross-sectional evaluation of venous thromboembolism risk and use of venous thromboembolism prophylaxis in hospitalized patients in Senegal. , 2011, Archives of cardiovascular diseases.

[45]  L. Lanthier,et al.  [Evaluation of thromboprophylaxis in patients hospitalized in a tertiary care center: an applicable model of clinical practice evaluation. Revision of 320 cases]. , 2011, Journal des maladies vasculaires.

[46]  P. Shahabi,et al.  Sticker reminders improve thromboprophylaxis appropriateness in hospitalized patients. , 2010, Thrombosis research.

[47]  Zachary A. Stacy,et al.  Impact of a Student-Supported Pharmacy Assessment Program on Venous Thromboembolism Prophylaxis Rates in Hospitalized Patients , 2010, American Journal of Pharmaceutical Education.

[48]  Samuel Z Goldhaber,et al.  Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study , 2008, The Lancet.

[49]  W. Riback.  DVT prophylaxis in relation to patient risk profiling – the TUNEIN study , 2022 .